Combination immunotherapy and mTOR inhibitor

This page covers all Combination immunotherapy and mTOR inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Interferon alfa receptor; mTOR.

Targets

Interferon alfa receptor; mTOR

Phase 3 pipeline (1)

• Interferon Alfa and CCI-779 · Pfizer · Oncology
  This combination uses interferon alfa to enhance immune activation while CCI-779 (temsirolimus) inhibits mTOR to suppress tumor cell proliferation and promote apoptosis.

Patent intelligence

• combination immunotherapy and mtor inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates